Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How should Abasaglar® (insulin glargine) be administered and dosed?

Abasaglar should be administered subcutaneously, once daily the same time each day.

UK_cFAQ_BIV033_ADMINISTRATION
UK_cFAQ_BIV033_ADMINISTRATION
en-GB

Administration Instructions

Before injection

Check the insulin label to avoid medication errors between Abasaglar and other insulins.1

Inspect Abasaglar and only use it if the solution is

  • clear
  • colourless
  • with no solid particles visible, and
  • of water-like consistency.1

Injection

Inject between 1 and 80 units of Abasaglar per injection.2

Administer subcutaneously into the abdominal area, thigh, or deltoid.3

Rotate injection sites within the same region to reduce the risk of lipodystrophy and cutaneous amyloidosis.1

Do not dilute or mix Abasaglar with any other insulin or or medicinal products. Mixing or diluting can change its time/action profile and mixing can cause precipitation.1

Do not administrate Abasaglar intravenously. 

The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue.  Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.1

Dosing Instructions

Inject Abasaglar at any time of day.1

Adapt the dose regimen of Abasaglar based on the individual’s needs.1

Perform dosage adjustments of Abasaglar under medical supervision and with appropriate glucose monitoring.

Dosage adjustments may be needed with

  • changes in physical activity
  • changes in meal patterns
  • episodes of acute illness, or
  • changes in renal or hepatic function.1

References

1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Abasaglar [instructions for use]. Eli Lilly Nederland B.V., The Netherlands .

3Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 05 April 2022


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request